Program
reproxalap
Also written as “Reproxalap Ophthalmic Solution (0.25%)”, “Reproxalap Ophthalmic Solution (0.5%)” and “ADX-102 Ophthalmic Solution (0.5%)”.
Its studies are mostly in Dry Eye Syndromes · Conjunctivitis, Allergic · Alopecia Areata · Uveitis, Anterior, led by 2 companies.
Drug pageReproxalap: every studyAll 20 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Aldeyra Therapeutics | 200 open or running | phase 3since Apr 4, 2017 | Dec 14, 2016 | none ahead |
| Aldena Therapeuticsits history only | 11 open or running | phase 2since Jan 22, 2025 | Jan 22, 2025 | Nov 2026phase 2 · NCT06826196 |
Also a collaborator on its studies: ORA.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Aldeyra Therapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 6 studies since Dec 14, 2016.
- Jun 9, 2018Named reproxalapINNProposed as its International Nonproprietary Name in WHO's List 119
- Aug 31, 2018Phase 2 study in Conjunctivitis, AllergicNCT03660878 · 52 enrolled · United States
- Oct 3, 2018Phase 2 study in Conjunctivitis, AllergicNCT03709121 · 70 enrolled · Canada
- Mar 15, 2019Phase 3 study in Dry Eye SyndromesNCT03879863 · 422 enrolled · United States
- Dec 19, 2019Phase 3 study in Conjunctivitis, AllergicNCT04207736 · 95 enrolled · Canada
- Dec 14, 2020Phase 3 study in Dry Eye SyndromesNCT04674358 · 329 enrolled · United States
- Jan 25, 2021Phase 3 study in Dry Eye SyndromesNCT04735393 · 757 enrolled · United States
- Jul 12, 2021Phase 2 study in Dry Eye SyndromesNCT04971031 · 158 enrolled · United States
- Sep 13, 2021Phase 3 study in Dry Eye SyndromesNCT05062330 · 361 enrolled · United States
- Oct 18, 2021Phase 2 study in Dry Eye SyndromesNCT05102409 · 56 enrolled · Canada
- Feb 1, 2022Phase 3 study in Conjunctivitis, AllergicNCT05234554 · 131 enrolled · Canada
- Jun 15, 2022Phase 2 study in Dry Eye SyndromesNCT05424549 · 63 enrolled · Canada
- Apr 25, 2024Phase 3 study in Dry Eye SyndromesNCT06389214 · 132 enrolled · Canada
- May 17, 2024Phase 3 study in Dry Eye SyndromesNCT06424444 · 421 enrolled · United States
- Jul 2, 2024Phase 3 study in Dry Eye SyndromesNCT06493604 · 116 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 20 Aldeyra Therapeutics leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06493604Dry Eye Syndromes · United States | 3 | Completed | Feb 27, 2025 | 116 |
| NCT06424444Dry Eye Syndromes · United States | 3 | Completed | Nov 3, 2024 | 421 |
| NCT06389214Dry Eye Syndromes · Canada | 3 | Completed | Jun 11, 2024 | 132 |
| NCT05424549Dry Eye Syndromes · Canada | 2 | Completed | May 9, 2022 | 63 |
| NCT05234554Conjunctivitis, Allergic · Canada | 3 | Completed | Apr 22, 2023 | 131 |
| NCT05102409Dry Eye Syndromes · Canada | 2 | Completed | Oct 25, 2021 | 56 |
| NCT05062330Dry Eye Syndromes · United States | 3 | Completed | Mar 4, 2022 | 361 |
| NCT04971031Dry Eye Syndromes · United States | 2 | Completed | Sep 8, 2021 | 158 |
| NCT04735393Dry Eye Syndromes · United States | 3 | Completed | Oct 11, 2022 | 757 |
| NCT04674358Dry Eye Syndromes · United States | 3 | Completed | Sep 12, 2021 | 329 |
| NCT04207736Conjunctivitis, Allergic · Canada | 3 | Completed | Feb 16, 2021 | 95 |
| NCT03879863Dry Eye Syndromes · United States | 3 | Completed | Oct 4, 2019 | 422 |
| NCT03709121Conjunctivitis, Allergic · Canada | 2 | Completed | Mar 20, 2019 | 70 |
| NCT03660878Conjunctivitis, Allergic · United States | 2 | Completed | Nov 19, 2019 | 52 |
| NCT03494504Conjunctivitis, Allergic · United States | 3 | Completed | Nov 5, 2018 | 318 |
| NCT03445650Sjogren-Larsson Syndrome · United States | 3 | Completed | Jan 18, 2020 | 11 |
| NCT03404115Dry Eye Syndromes · United States | 2 | Completed | Jul 11, 2018 | 300 |
| NCT03162783Dry Eye Syndromes · United States | 2 | Completed | Jul 6, 2017 | 51 |
| NCT03131154Non-infectious Anterior Uveitis · United States | 3 | Completed | Apr 19, 2019 | 123 |
| NCT03012165Conjunctivitis, Allergic · United States | 2 | Completed | May 2017 | 154 |
How it is read
Names in the registry
- “Reproxalap Ophthalmic Solution (0.25%)”, 15 entries
- “Reproxalap Ophthalmic Solution (0.5%)”, 3 entries
- “ADX-102 Ophthalmic Solution (0.5%)”, 2 entries
- “ALD-102 Solution”, 1 entry
- “Reproxalap ophthalmic solution (0.25%)”, 1 entry
Conditions, from the studies’ own filings
- Dry Eye Syndromes, 12 studies
- Conjunctivitis, Allergic, 6 studies
- Alopecia Areata, 1 study
- Uveitis, Anterior, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.